Tags

Type your tag names separated by a space and hit enter

[Bone and calcium metabolism associated with malignancy. Malignancy-associated hypercalcemia.]
Clin Calcium. 2018; 28(11):1503-1508.CC

Abstract

Hypercalcemia is a poor prognostic factor and can be a direct cause of death in patients with malignancy. Here we provide a brief overview of pathology, etiology and management of malignancy associated hypercalcemia(MAH). MAH can be divided into two categories:humoral hypercalcemia of malignancy(HHM)caused by a systemic soluble factor secreted by the tumor;and local osteolytic hypercalcemia(LOH)in which tumor cells in situ enhance bone resorption. The standard treatment of MAH is intense hydration along with antiresorptive medications such as calcitonin, bisphosphonate and denosumab.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Tai N
Third Department of Medicine, Teikyo University School of Medicine, Japan.
Inoue D
Third Department of Medicine, Teikyo University School of Medicine, Japan.

MeSH

Bone ResorptionCalcitoninCalciumDenosumabDiphosphonatesHumansHypercalcemiaNeoplasmsParaneoplastic Syndromes

Pub Type(s)

Journal Article
Review

Language

jpn

PubMed ID

30374007

Citation

Tai, Nobuyuki, and Daisuke Inoue. "[Bone and Calcium Metabolism Associated With Malignancy. Malignancy-associated Hypercalcemia.]." Clinical Calcium, vol. 28, no. 11, 2018, pp. 1503-1508.
Tai N, Inoue D. [Bone and calcium metabolism associated with malignancy. Malignancy-associated hypercalcemia.]. Clin Calcium. 2018;28(11):1503-1508.
Tai, N., & Inoue, D. (2018). [Bone and calcium metabolism associated with malignancy. Malignancy-associated hypercalcemia.]. Clinical Calcium, 28(11), 1503-1508. https://doi.org/CliCa181115031508
Tai N, Inoue D. [Bone and Calcium Metabolism Associated With Malignancy. Malignancy-associated Hypercalcemia.]. Clin Calcium. 2018;28(11):1503-1508. PubMed PMID: 30374007.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Bone and calcium metabolism associated with malignancy. Malignancy-associated hypercalcemia.] AU - Tai,Nobuyuki, AU - Inoue,Daisuke, PY - 2018/10/31/entrez PY - 2018/10/31/pubmed PY - 2019/6/22/medline SP - 1503 EP - 1508 JF - Clinical calcium JO - Clin Calcium VL - 28 IS - 11 N2 - Hypercalcemia is a poor prognostic factor and can be a direct cause of death in patients with malignancy. Here we provide a brief overview of pathology, etiology and management of malignancy associated hypercalcemia(MAH). MAH can be divided into two categories:humoral hypercalcemia of malignancy(HHM)caused by a systemic soluble factor secreted by the tumor;and local osteolytic hypercalcemia(LOH)in which tumor cells in situ enhance bone resorption. The standard treatment of MAH is intense hydration along with antiresorptive medications such as calcitonin, bisphosphonate and denosumab. SN - 0917-5857 UR - https://www.unboundmedicine.com/medline/citation/30374007/[Bone_and_calcium_metabolism_associated_with_malignancy__Malignancy_associated_hypercalcemia_] DB - PRIME DP - Unbound Medicine ER -